$2.640
0.000 (0.00%)At close
QTRX News
QTRX Events
Quanterix Advances Milestones in Blood-Based Alzheimer's Testing
The company "announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer's testing. Together, these milestones reinforce the growing role of LucentAD(R) Complete, Quanterix's five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer's disease through a comprehensive, blood-based assessment. The announcements include: Anthem Blue Cross and Blue Shield eligible members will be the first commercially insured patients in the United States to benefit from medical policy coverage supporting blood-based biomarker testing for Alzheimer's disease; Publication of new peer-reviewed study comparing LucentAD(R) Complete against an immunoprecipitation mass spectrometry (IP-MS) method on a shared patient cohort, demonstrating strong diagnostic parity while combining five biomarkers across amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation; New clinical data presented at the Alzheimer's Association International Conference (AAIC) 2026 highlighting the role of multi-biomarker testing in supporting patient triage and supporting earlier clinical decision making."
Quanterix Appoints Geoff Albrecht as SVP and GM of Diagnostics
Quanterix Corporation (QTRX) announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quanterix's Diagnostics portfolio into a significant revenue driver. He will report directly to the CEO and serve as a member of the Executive Leadership Team. Albrecht brings more than 25 years of distinguished commercial leadership experience from Quest Diagnostics (DGX), where he served as Regional Vice President for the Northeast U.S. region.
Quanterix CFO Vandana Sriram to Depart
Quanterix "announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition."
Company Reports Q1 Revenue of $36.4M, Below Consensus
Reports Q1 revenue $36.4M, consensus $36.84M. The company said, ""We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition. As part of this process, we are focusing our investment into areas that will benefit our commercial effectiveness and drive improved operating results in 2026 and beyond. Additionally, our Alzheimer's diagnostics business continues its rapid growth with several key milestones expected in the second half of this year, including the completion of three clinical utility studies and a decision from the FDA on our 510(k) application."
Quanterix Reaffirms 2026 Revenue Guidance of $169 to $174 Million
The company said, "Quanterix is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutical end markets. Quanterix anticipates GAAP gross margin of 41% to 45%, and adjusted gross margin (non-GAAP) of 49% to 53%. In the first quarter, Quanterix changed its accounting policy for classifying shipping and handling costs for product sales to record them within gross margin. Historically, these costs were recorded in selling, general and administrative expenses. This reclassification is reflected in the Company's GAAP guidance range, but there is no change to the non-GAAP margin expectation. Quanterix continues to anticipate achieving cash flow breakeven in the second half of the year and expects to end the year with cash in the range of $100M, and no debt."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.